Policlinico San Donato IRCCS, Cardiovascular Center E. Malan, University of Milano, via Morandi 30, 20097 San Donato Milanese, Italy.
Circulation. 2010 Sep 28;122(13):1283-9. doi: 10.1161/CIRCULATIONAHA.109.929422. Epub 2010 Sep 13.
In patients with acute type B aortic dissection, presence of recurrent or refractory pain and/or refractory hypertension on medical therapy is sometimes used as an indication for invasive treatment. The International Registry of Acute Aortic Dissection (IRAD) was used to investigate the impact of refractory pain and/or refractory hypertension on the outcomes of acute type B aortic dissection.
Three hundred sixty-five patients affected by uncomplicated acute type B aortic dissection, enrolled in IRAD from 1996 to 2004, were categorized according to risk profile into 2 groups. Patients with recurrent and/or refractory pain or refractory hypertension (group I; n=69) and patients without clinical complications at presentation (group II; n=296) were compared. "High-risk" patients with classic complications were excluded from this analysis. The overall in-hospital mortality was 6.5% and was increased in group I compared with group II (17.4% versus 4.0%; P=0.0003). The in-hospital mortality after medical management was significantly increased in group I compared with group II (35.6% versus 1.5%; P=0.0003). Mortality rates after surgical (20% versus 28%; P=0.74) or endovascular management (3.7% versus 9.1%; P=0.50) did not differ significantly between group I and group II, respectively. A multivariable logistic regression model confirmed that recurrent and/or refractory pain or refractory hypertension was a predictor of in-hospital mortality (odds ratio, 3.31; 95% confidence interval, 1.04 to 10.45; P=0.041).
Recurrent pain and refractory hypertension appeared as clinical signs associated with increased in-hospital mortality, particularly when managed medically. These observations suggest that aortic intervention, such as via an endovascular approach, may be indicated in this intermediate-risk group.
在急性 B 型主动脉夹层患者中,疼痛反复发作或药物治疗无法控制的高血压有时被用作介入治疗的指征。国际急性主动脉夹层注册研究(IRAD)用于调查疼痛反复发作或药物治疗无法控制的高血压对急性 B 型主动脉夹层患者结局的影响。
IRAD 于 1996 年至 2004 年纳入 365 例单纯性急性 B 型主动脉夹层患者,根据风险特征分为 2 组。组 1(n=69)为疼痛反复发作和/或药物治疗无法控制的高血压或疼痛或高血压药物治疗无法控制的患者,组 2(n=296)为无临床并发症的患者。该分析排除了具有经典并发症的“高危”患者。总体院内死亡率为 6.5%,组 1高于组 2(17.4%比 4.0%;P=0.0003)。与组 2 相比,组 1 经药物治疗后的院内死亡率明显升高(35.6%比 1.5%;P=0.0003)。与组 2 相比,组 1 经手术(20%比 28%;P=0.74)或血管内治疗(3.7%比 9.1%;P=0.50)后的死亡率差异无统计学意义。多变量逻辑回归模型证实,疼痛反复发作和/或药物治疗无法控制的高血压是院内死亡率的预测因素(比值比,3.31;95%置信区间,1.04 至 10.45;P=0.041)。
疼痛反复发作和药物治疗无法控制的高血压是与院内死亡率增加相关的临床征象,尤其是在药物治疗时。这些观察结果表明,在这种中危患者中,主动脉介入治疗,如血管内治疗,可能是必要的。